Testing VTx-002 for safety in ALS patients
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This trial tests a new drug called VTx-002 to see if it is safe and tolerable for people with ALS. You may be able to join if you have had symptoms for less than 18 months and have a caregiver who can help.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and have a diagnosis of ALS (probable or definite).
- You must have had your first muscle weakness symptoms within the last 18 months.
- You must have a caregiver or family member who can help you with the study.
- You must have good lung function (at least 80% of expected for your age and height).
- You cannot have ALS caused by FUS or SOD1 gene mutations.
- You cannot have other major health problems like heart disease, diabetes, or cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies an experimental drug called LTX-002 for people with ALS. It aims to see if the drug is safe and can slow down the disease.
This trial tests a new treatment aimed at restoring the function of a gene called UNC13A in people with ALS. It involves multiple clinic visits, MRI scans, and spinal taps to see if the treatment is safe and may slow the disease.
This trial tests a new way of giving riluzole, a medicine already used for ALS, by delivering it directly into the fluid around the spinal cord using a small pump. It aims to see if this method is safe and might work better for people with ALS.
This study is testing whether injecting special cells (called Q-Cells) into the spinal cord is safe for people with ALS. It's an early-stage trial, so the main goal is to check safety, but it might help slow down the disease in the future.
This study tests an experimental drug called PLL001 for people with ALS. It aims to see if the drug is safe and whether it can slow the progression of the disease.
This trial tests whether adding two supplements (EH-301 and N-acetylcysteine) to the standard ALS medicine Riluzole can help slow the disease. It is for people diagnosed with ALS within the last 18 months who still have good breathing and daily function.
Hear when a new Amyotrophic Lateral Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.